Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03862911




Registration number
NCT03862911
Ethics application status
Date submitted
8/02/2019
Date registered
5/03/2019
Date last updated
29/07/2024

Titles & IDs
Public title
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer
Scientific title
Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)
Secondary ID [1] 0 0
SABR-COMET-3
Universal Trial Number (UTN)
Trial acronym
SABR-COMET-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - palliative radiotherapy
Treatment: Other - Stereotactic ablative radiotherapy

Active comparator: Standard of Care Treatment (Arm 1) - Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist

Experimental: Stereotactic Arm (Arm 2) - Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist


Treatment: Other: palliative radiotherapy
Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.

Treatment: Other: Stereotactic ablative radiotherapy
Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily

Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily

Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily

Liver: 54 Gy/3#, every second day

Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily

Lymph Node: 40 Gy/5#, daily
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival
Timepoint [1] 0 0
At approximately end of year 5 (study completion)
Secondary outcome [1] 0 0
Side effects
Timepoint [1] 0 0
At 6 weeks, 3 months, 6 months, and every 6 months post treatment for years 1 and 2. At approximately end of years 3, 4, and 5.
Secondary outcome [2] 0 0
Progression-free survival (PFS)
Timepoint [2] 0 0
At 6 weeks, 3 months, 6 months, and every 6 months post treatment for years 1 and 2. At approximately end of years 3, 4, and 5.
Secondary outcome [3] 0 0
Patient-reported quality of life (QoL)
Timepoint [3] 0 0
At baseline, 6 weeks, 3 months, 6 months, and every 6 months post treatment for years 1 and 2. At approximately end of years 3, 4, and 5.
Secondary outcome [4] 0 0
Health-related quality of life (HRQoL) questionnaire
Timepoint [4] 0 0
At baseline, 3 months, 6 months, and every 6 months post treatment for years 1 and 2. At approximately end of years 3, 4, and 5.
Secondary outcome [5] 0 0
Resource Utilization (Patient and Provider Reported)
Timepoint [5] 0 0
At 3 months, 6 months, and every 6 months post treatment for years 1 and 2. At approximately end of years 3, 4, and 5.
Secondary outcome [6] 0 0
Correlation between candidate biomarkers of oligometastatic disease (blood-derived) and oncologic outcomes
Timepoint [6] 0 0
At baseline, 3 months, and disease progression or study completion (Year 5)

Eligibility
Key inclusion criteria
* Total number of 1-3 current metastases, and a maximum 8 lifetime metastases
* Age 18 or older
* Willing to provide informed consent
* ECOG score 0-2
* Life expectancy >6 months
* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
* Controlled primary tumor

* defined as: at least 3 months since original tumor treated definitively, with no progression at primary site (can be considered controlled if no evidence of the primary tumour on imaging)
* A history and physical exam, including ECOG performance status, performed within 6 weeks prior to trial enrollment
* Not suitable for resection at all sites or decline surgery
* Patient has had a CT chest, abdomen and pelvis or PET-CT within 8 weeks prior to enrollment, and within 12 weeks prior to treatment(if randomized to SABR). CT neck as clinically indicated.
* Patient has had a nuclear bone scan (if no PET-CT) within 8 weeks prior to enrollment, and within 12 weeks prior to treatment(if randomized to SABR)
* If solitary lung nodule for which biopsy is unsuccessful or not possible, patient has had an FDG PET scan or CT (chest, abdomen, pelvis) and bone scan within 8 weeks prior to enrollment, and with 12 weeks prior to treatment (if randomized to SABR). CT neck as clinically indicated.
* If colorectal primary with rising CEA, but equivocal imaging, patient has had an FDG PET scan within 8 weeks prior to enrollment, and within 12 weeks prior to treatment(if randomized to SABR)
* Patient has had CT or MRI brain imaging if primary has a propensity for CNS metastasis within 8 weeks prior to enrollment, and within 12 weeks prior to treatment(if randomized to SABR)
* Patient is judged able to:
* Maintain a stable position during therapy
* Tolerate immobilization device(s) that may be required to deliver SABR safely
* Negative pregnancy test for Women of Child-Bearing potential (WOCBP) within 4 weeks of RT start date
* Patient is able and willing to complete the quality of life questionnaires, and other assessments that are a part of this study, via paper or online using REDCap (if email address is provided by participant on the informed consent)

Waivers to the inclusion criteria will NOT be allowed.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Lesion in femoral bone requiring surgical fixation
* Chemotherapy agents (cytotoxic, or molecularly targeted agents) used within the period of time commencing 2 weeks prior to radiation, lasting until 1 week after the last fraction for patients randomized to SABR
* Serious medical comorbidities precluding radiotherapy. These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the GI tract will receive radiotherapy, and connective tissue disorders such as lupus or scleroderma.
* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with conventional radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed below. All such cases should be discussed with one of the study PIs.
* Concurrent malignant cancer, or history of malignant cancers within the past 5 years
* Malignant pleural effusion
* History of poor lung function (if treating near lung)
* History of poor liver function (if treating near liver)
* Inability to treat all sites of disease
* Maximum size of 5 cm for lesions outside the brain, except:

* Bone metastases over 5 cm may be included, if in the opinion of the local PI it can be treated safely (e.g. rib, scapula, pelvis)
* Any brain metastasis >3 cm in size or a total volume of brain metastases greater than 30 cc.
* Clinical or radiologic evidence of spinal cord compression, or epidural tumor within <2 mm of the spinal cord. Patients can be eligible if surgical resection has been performed, but the surgical site counts toward the total of up to 8 lifetime metastases.
* Dominant brain metastasis requiring surgical decompression
* Pregnant or breastfeeding women

Waivers to exclusion criteria will NOT be allowed.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2030
Actual
Sample size
Target
330
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Cancer Care Griffith - Griffith
Recruitment hospital [2] 0 0
Riverina Cancer Care Centre - Wagga Wagga
Recruitment hospital [3] 0 0
Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Griffith
Recruitment postcode(s) [2] 0 0
2650 - Wagga Wagga
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Alberta
Country [2] 0 0
Canada
State/province [2] 0 0
British Columbia
Country [3] 0 0
Canada
State/province [3] 0 0
Ontario
Country [4] 0 0
Ireland
State/province [4] 0 0
Dublin
Country [5] 0 0
Ireland
State/province [5] 0 0
Sandyford
Country [6] 0 0
Ireland
State/province [6] 0 0
Cork
Country [7] 0 0
United Kingdom
State/province [7] 0 0
Scotland
Country [8] 0 0
United Kingdom
State/province [8] 0 0
Glasgow

Funding & Sponsors
Primary sponsor type
Other
Name
British Columbia Cancer Agency
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
London Regional Cancer Program, Canada
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
The Alfred
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Beacon Hospital, Ireland
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Cancer Trials Ireland
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
Cancer Research UK Edinburgh Centre
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
Bon Secours Cork Cancer Centre
Address [6] 0 0
Country [6] 0 0
Other collaborator category [7] 0 0
Other
Name [7] 0 0
UPMC Hillman Cancer Centre
Address [7] 0 0
Country [7] 0 0
Other collaborator category [8] 0 0
Other
Name [8] 0 0
Beatson West of Scotland Cancer Centre
Address [8] 0 0
Country [8] 0 0
Other collaborator category [9] 0 0
Other
Name [9] 0 0
Tom Baker Cancer Centre
Address [9] 0 0
Country [9] 0 0
Other collaborator category [10] 0 0
Other
Name [10] 0 0
Walker Family Cancer Centre
Address [10] 0 0
Country [10] 0 0
Other collaborator category [11] 0 0
Other
Name [11] 0 0
Riverina Cancer Care Centre
Address [11] 0 0
Country [11] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Robert A Olson, MD, MSc, FRCPC
Address 0 0
BC Cancer Prince George
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Robert Olson, MD, MSc, FRCPC
Address 0 0
Country 0 0
Phone 0 0
250-645-7300
Fax 0 0
Email 0 0
rolson2@bccancer.bc.ca
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03862911